Pain-relieving drugs and the brain histaminergic system: multiple analgesic mechanisms from histamine, improgan and cimetidine.
Pain-relieving drugs and the brain histaminergic system: multiple analgesic mechanisms from histamine, improgan and cimetidine.
复制标题
止痛药物和大脑组胺能系统:组胺、伊普甘和西咪替丁的多种镇痛机制。
DOI:
10.1007/s00011-003-0320-7
复制
发表时间:
2004
期刊:
影响因子:
--
通讯作者:
Timmermann,H
中科院分区:
文献类型:
--
作者:
Hough,LB;Nalwalk,JW;Svokos,K;Leurs,R;Timmermann,H
Injections of histamine into the CNS produce powerful antinociception [1], but the role of the brain histaminergic system in pain relief has remained poorly understood. The periaqueductal grey (PAG), innervated by histaminergic neurons, is known to be an essential component of multiple, descending opioid and non-opioid pain-relieving systems which are linked to emotional states and are activated by environmental variables [2]. In the PAG, histamine activates both H1 and H2 receptors to reduce pain transmission [1], but H2 receptors in this region are necessary for morphine antinociception and for non-opioid stress-induced antinociception [3].Characterization of antinociceptive responses related to H2 receptors led to the unexpected discovery that centrallyadministered H2 antagonists such as cimetidine have antinociceptive activity [4]. Testing of compounds chemically related to H2 and H3 antagonists led to the discovery of improgan, a cimetidine derivative which induces powerful CNS antinociception, but does not block the H2 receptor [4]. Chemical structures of histamine, cimetidine and improgan are given in Fig. 1. Like morphine, improgan attenuates thermal and mechanical nociceptive responses, and shows the profile of a highly effective analgesic drug [5]. However, improgan does not act through known opioid or histamine receptors [5]. Although in vitro studies have excluded over 50 CNS receptors and ion channels [5], the search for the improgan receptor continues. In vivo, improgan seems to activate descending, brain stem pain-relieving circuitry in the PAG and raphe magnus which may involve supraspinal GABAergic and cannabinoid systems, as well as spinal noradrenergic systems [5–7]. The drug does not act directly on any of these receptors, however.